Bernstein initiates Swiggy stock with Outperform rating on quick commerce potential

Bernstein has lowered its price target for Costco's stock to $1,134, citing a pullback in valuation. This adjustment reflects concerns about the company's future performance and market conditions, which could impact investor confidence. Understanding these changes is crucial for shareholders and potential investors as they navigate the stock market.

Bernstein has raised its price target for Grab's stock to $6.60, reflecting the company's consistent performance in the market. This adjustment is significant as it indicates investor confidence in Grab's growth potential and operational stability, which could attract more investors and positively influence the stock's performance.

Eaton's stock has seen a notable rise following Bernstein's decision to reiterate an 'Outperform' rating on the company's liquid cooling deal. This endorsement from Bernstein highlights the potential growth and profitability of Eaton's innovative cooling solutions, which are becoming increasingly important in the tech industry. Investors are optimistic about Eaton's future prospects, making this a significant moment for the company.

Bernstein has downgraded Charter Communications, citing increased competition as a significant factor limiting the company's earnings growth. This decision highlights the challenges Charter faces in a rapidly evolving telecommunications landscape, where rivals are gaining ground. Investors should pay attention to how this shift may impact Charter's market position and financial performance moving forward.

Bernstein has reaffirmed its 'Outperform' rating for Eli Lilly following a strong performance in the third quarter. This endorsement highlights the company's robust financial health and growth potential, which is significant for investors looking for reliable stocks in the pharmaceutical sector.

Bernstein has reaffirmed its Outperform rating for Gilead Sciences, citing the company's strong performance in the HIV market. This is significant as it highlights investor confidence in Gilead's ability to maintain its leadership in a crucial therapeutic area, which could lead to increased stock value and investor interest.

Bernstein has lowered its price target for BioMarin's stock to $88 due to concerns about the company's growth prospects. This adjustment reflects a cautious outlook on BioMarin's ability to expand and meet market expectations, which could impact investor confidence and the stock's performance in the near future.

Bernstein has raised its price target for Biogen's stock to $157, following a strong performance in its multiple sclerosis (MS) franchise. This adjustment reflects confidence in Biogen's growth potential and the effectiveness of its treatments, which is significant for investors and patients alike. The increase in target price indicates a positive outlook for the company's future, especially as it continues to innovate in the MS treatment space.

Cava, the fast-casual restaurant chain, has revised its full-year outlook, now anticipating same-restaurant sales growth of only 3% to 4%, a decrease from the previous estimate of 4% to 6%. This slowdown in growth reflects challenges the company is facing in the current market.

Pinterest reported a 17% increase in sales for the third quarter but anticipates a slowdown in revenue growth for the fourth quarter, projecting an increase of only 14% to 16%. This shift highlights the challenges the platform faces in maintaining its growth momentum.

In the latest episode of the Big Take Asia podcast, the discussion focuses on how major Asian economies are managing the increasing tensions between the US and China following the recent APEC summit.

Investors are feeling uneasy as the S&P 500 and Nasdaq experienced their largest one-day declines in weeks. This downturn follows announcements from major tech companies regarding their AI spending plans for 2026, raising concerns about the sustainability of such investments.

Digital Turbine has reported its Q2 2026 earnings, surpassing expectations and showcasing strong financial performance. This positive outcome reflects the company's effective strategies and growth in the digital marketplace.

Cumberland Pharmaceuticals reported impressive revenue growth in their Q3 2025 earnings call, showcasing strong performance and positive market response. The company highlighted key strategies that contributed to this success, indicating a promising future ahead.